平特五不中

平特五不中.CA / D2R / About

Governance

平特五不中

D2R Governance Framework

Board of Directors and Executive Committee

The mandate of the Board includes contributions to the oversight of the appropriate governance, management and personnel structures, policies, procedures, and strategies, including those related to the Risk and Mitigation Plan (RMP), to the Performance Measurement Plan (PMP), to management of conflict of interest (COI), and to criteria for funding eligibility and performance-based evaluations. The Board also contributes to the evaluation of the Resource allocation processes used to meet the ambitious objectives, and to monitoring access to designated groups according to the D2R plan for Equity, Diversity and Inclusion and Indigenous Reconciliation (EDI-IR). The Board reviews D2R expenditures in relation to the alignment with the Canada First Research Excellence Fund, and to the institutional and scientific priorities and plans set out in the approved proposal as implemented taking into account the need to respond to the rapidly evolving scientific and translational landscapes.

  • Dominique B茅rub茅, Vice-President, Research and Innovation, 平特五不中 (Chair)
  • Alan Bernstein, C.C., professor of Global Health, University of Oxford; professor emeritus, University of Toronto; president emeritus, CIFAR and CIHR
  • Diane C么t茅, Executive Consultant, Innovitech Inc.
  • Lesley Fellows, Dean, Faculty of Medicine and Health Sciences, 平特五不中
  • Pamela Fralick, Principal, PCF Executive Leadership; Board Director
  • Minnie Grey, Former Executive Director, Nunavik Regional Board of Health and Social Services
  • Lakshmi Krishnan, Vice-President of Life Sciences, National Research Council of Canada
  • Josette-Ren茅e Landry, President and CEO, G茅nome Qu茅bec
  • Mark Lathrop, Scientific Director, Victor Phillip Dahdaleh Institute of Genomic Medicine, 平特五不中
  • R. Bruce Lennox, Dean of Science, 平特五不中
  • Mark Lievonen, Principal, JML Advisory Services; Co-Chair of Canada鈥檚 COVID-19 Vaccine Task Force
  • Anthony Monaco, University Professor and President Emeritus, Tufts University
  • Gail C. Murphy, Vice-President, Research & Innovation, University of British Columbia
  • Jean-Pierre Perreault, Vice President of Research and Higher Education, Universit茅 de Sherbrooke
  • Barry Stein, President and CEO, Colorectoral Cancer Canada
  • Sarah Viehbeck, Chief Science Officer, Public Health Agency of Canada
  • David Wright, Acting Associate Provost, Academic Policies and Faculty Affairs, 平特五不中

Research Steering Committee and Executive (RSC)

The RSC oversees and directs the scientific strategy of the D2R Initiative and its evolution in the face of rapid scientific and technological advances. The overarching mission and mandate of the RSC is to help deliver the initiative鈥檚 ambitious goals at a competitive pace and within the stated timelines. Supported by experts at 平特五不中 and at partner institutions, and by the D2R External Scientific Advisory Board (ESAB), the RSC mandate is to identify research areas of strategic priority, and in which the D2R Initiative stands to make a unique and original contribution (defining the D2R advantage). To achieve its mandate, the RSC engages in interactions with core researchers at 平特五不中 and at partner institutions and takes a proactive role in identifying and pursuing key technologies and research opportunities locally, nationally, and internationally. To help and assist in its broad mandate, the RSC may create punctual working groups consisting of experts who will make recommendations on the scientific direction of the Initiative. Furthermore, the RSC is responsible for coordinating engagement of the approved D2R research funding programs. It oversees scientific evaluation and resource allocation of the Initiative. It integrates existing and seeks new large-scale strategic research partnerships and collaborations. It establishes and evaluates the program's global position to assure that it is internationally competitive. The RSC works in close liaison with the Innovation and Partnerships Office of the Vice-Principal Research and Innovation in the commercialization of D2R research. The RSC organizes the meetings and closely interacts with the ESAB and the RSC sub-committees and receives their reports and recommendations for approval.

  • Philippe Gros, Deputy Vice-President, Research and Innovation, 平特五不中 (Chair)
  • Guillaume Bourque, Professor, Human Genetics, 平特五不中
  • Raquel Cuella Martin,聽Assistant Professor, Human Genetics
  • Treena Wasonti:io Delormier, Associate Professor, Human Nutrition, 平特五不中
  • Thomas Duchaine, Professor, Biochemistry, 平特五不中
  • Yann Joly, Professor, Human Genetics, 平特五不中
  • Amine Kamen, Professor, Bioengineering, 平特五不中
  • David Langlais, Associate Professor, Human Genetics, 平特五不中
  • Mark Lathrop, Professor, Human Genetics, 平特五不中, D2R Scientific Director
  • Maureen McKeague, Assistant Professor, Pharmacology and Therapeutics & Chemistry, 平特五不中
  • Vincent Mooser, Professor, Human Genetics, 平特五不中
  • Am茅lie Quesnel-Vall茅e, Inaugural Chair and Professor, Department of Equity, Ethics and Policy, School of Population and Global Health, Faculty of Medicine and Health Sciences and Professor, Department of Sociology, Faculty of Arts,聽平特五不中,聽D2R Associate Scientific Director
  • Ioannis Ragoussis, Professor, Human Genetics, 平特五不中
  • Stephen Robbins, Director, Lady Davis Research Institute at the Jewish General
  • Rhian Touyz, Professor of Medicine, 平特五不中
  • Maria Vera Ugalde, Assistant Professor, Biochemistry, 平特五不中
  • Silvia Vidal, Professor, Human Genetics, 平特五不中

External Scientific Advisory Board (ESAB)

The D2R External Scientific Advisory Board (ESAB) provides independent and objective scientific advice to the Research Steering Committee (RSC) and the scientific directors of D2R. The ESAB offers guidance on strategic directions related mission and goals of D2R by addressing scientific excellence and translational impacts, and it evaluates progress towards meeting the initiative goals. It contributes to the mandate of the RSC by identifying and commenting on key technologies, research opportunities and partnerships that will forward the initiative, and it evaluates resource allocation considering ambitious goals. It provides evaluations based on international comparisons that will help strengthen the Initiative and allow the RSC to adjust it to meet the challenges of a rapidly evolving scientific environment. ESAB meetings are organized by the D2R Scientific Director, who receives its reports and recommendations, with the aid of the D2R administrative office.

List of members forthcoming

External Indigenous Advisory Council (EIAC)

The External Indigenous Advisory Council (EIAC) provides advice to the Research Steering Committee (RSC) and the Partner and Community Engagement Committee (PCE) as well as the scientific leadership and D2R staff on the Indigenous health programs (engagement, training, research) and all interfaces with Indigenous partner organizations and communities.

The EIAC also informs and advises the RSC, scientific directors, the Chief Scientific Officer (CSO) and D2R staff of evolving priorities of Indigenous health, and benchmarks activities to national and international standards.

List of members forthcoming.

Investment and Commercialization Committee (ICC)

The ICC oversees all aspects of the D2R Initiative that relate to commercialization, innovation in the commercial space, entrepreneurship, and investment. The ICC facilitates engagement with industry, venture capitalists, funders, government agencies and programs (valorisation societies) and other stakeholders to enhance commercialization of D2R discoveries, technology transfer to and from industry, creation and support of novel commercial entities including spinoffs and joint ventures, and all other aspects of translation of knowledge into commercial products. The ICC provides oversight for the distribution of D2R financial resources to achieve these goals and objectives. To achieve its mandate, the ICC works with, and facilitates interactions between, the leadership of the D2R staff and the Innovation and Partnerships (I+P) Office of the Vice-President (Research and Innovation). ICC meetings are organized by the Research Steering Committee (RSC) of D2R, which receives its reports and recommendations.

  • Mark Weber, Director, Innovation and Partnerships, 平特五不中 (Chair)
  • Mounia Azzi, Vice President, Corporate Development, Admare Bio
  • Nawel Bailey, Founder and President, Haber Biologics
  • Diane Gosselin, President and CEO, CQDM
  • Philippe Gros, Deputy Vice-President, Research and Innovation, 平特五不中
  • In猫s Holzbaur, Founder and Managing Partner, AmorChem
  • Avak Khavejian,聽General聽Partner, Flagship Pioneering
  • Michael Mee, Principal, Amplitude Ventures
  • Marc Sauer, Chief Science Officer, BIOVECTRA

Partner and Community Engagement Committee (PCE)

Established under the authority of the D2R Research Steering Committee (RSC), the PCE Committee oversees D2R policies and processes to ensure that Indigeneity, equity, diversity, and inclusion are central to D2R decision-making. The PCE Committee provides guidance to the RSC, D2R staff and leadership on the development, implementation, and ongoing improvement of D2R鈥檚 EDI Action Plan. The aims of the Action Plan are to support the improved consideration of EDI across D2R鈥檚 funding programs, policies, processes, and funded research as well as in the greater 平特五不中 community and promote an inclusive and accessible environment for all, with a particular focus on the six 平特五不中 designated groups (Women, Persons with Disabilities, Indigenous Peoples, Visible Minorities, Ethnic Minorities and Sexual Orientation & Gender Identity Minorities). The PCE Committee also provides guidance on partner engagement, recommending an action plan to ensure that decision-making is inclusive of end-user community and partner perspectives as well as targeted training on inclusive research and data practices (e.g., Sex & Gender-based Analysis+ (SGBA+) analytics, participant privacy, CARE Principles for Indigenous Data Governance).

  • Raquel Cuella-Martin, Assistant Professor, Human Genetics, 平特五不中 (Chair)
  • Paul Wankah, Assistant Professor, Dental Medicine and Oral Health Sciences,聽平特五不中聽(Vice Chair)
  • Tynan Jarrett, Director, Equity, Diversity, & Inclusion, Office of the Provost and Vice-President
  • Yann Joly, Professor, Human Genetics, 平特五不中
  • Lara Khoury, Full Professor, Law, and Associate Vice-President (Research),聽平特五不中聽
  • Nathan Luedtke, Professor, Chemistry,聽平特五不中
  • Vincent Mooser, Professor, Human Genetics,聽平特五不中
  • Am茅lie Quesnel-Vall茅e, Inaugural Chair and Professor, Department of Equity, Ethics and Policy, School of Population and Global Health, Faculty of Medicine and Health Sciences and Professor, Department of Sociology, Faculty of Arts, 平特五不中, D2R Associate Scientific Director

Student Training and Knowledge Development Committee (STaKD)

Established under the authority of the D2R Research Steering Committee (RSC), the STaKD Committee guides D2R鈥檚 funding and programming for graduate students and postdoctoral fellows. The STaKD Committee provides advice and guidance to the RSC and D2R staff and leadership on the development, implementation, ongoing improvement and monitoring of D2R鈥檚 training activities.

  • Am茅lie Quesnel-Vall茅e,聽 Inaugural Chair and Professor, Department of Equity, Ethics and Policy, School of Population and Global Health, Faculty of Medicine and Health Sciences and Professor, Department of Sociology, Faculty of Arts, 平特五不中, D2R Associate Scientific Director (Chair)
  • Guojun Chen, Assistant Professor, Biomedical Engineering, 平特五不中
  • Celia Greenwood,聽Professor, Oncology, and Epidemiology, Biostatistics and Occupational Health, and Division of Cancer Epidemiology, 平特五不中
  • Maureen McKeague, Assistant Professor, Chemistry, 平特五不中
  • Josephine Nalbantoglu, Dean of Graduate and Postdoctoral Studies, 平特五不中
  • St茅phane Richard, Professor, Oncology and Medicine, 平特五不中
  • Mark Weber, Director, Innovation + Partnerships, 平特五不中
Back to top